These changes in weight and body composition increase the risk for cardiometabolic diseases, as evidenced by the increased prevalence of type 2 diabetes, dyslipidemia, metabolic dysfunction-associated steatotic liver disease (MASLD-previously referred to as nonalcoholic fatty liver disease) and cardiovascular disease (CVD) after menopause. How was the study set up
[DOI] [PubMed] [Google Scholar] 116.Knudsen L.B., Lau J
Do all GLP-1 medications cause the same level of fatigue
If youd like some additional (and more enjoyable) reading about participation in Phase 1 trials, Scott Alexander posted this from an anonymous Astral Codex Ten reader about the topic
They want something that works and keeps working
The observed outcomes were particularly significant in fibroblast-like synoviocytes, key players in RA pathogenesis, with the following main effects: (1) inhibition of NF-B nuclear translocation, leading to a decrease in the production of pro-inflammatory cytokines, including TNF, IL-6, IL-8, IL-1, MCP-1, and High Mobility Group Box (HMGB)-1, all of which are involved in RA progression
.jpg)
